Pettit Tristan, Cole Nyree, Leung Wingchi, Ballantine Kirsten, Macfarlane Scott
Children's Haematology Oncology Centre, Christchurch Hospital, Christchurch, New Zealand.
Starship Blood and Cancer Centre, Starship Children's Hospital, Auckland, New Zealand.
Pediatr Blood Cancer. 2017 Dec;64(12). doi: 10.1002/pbc.26676. Epub 2017 Jun 9.
The frequency of common cytogenetic abnormalities in pediatric acute lymphoblastic leukemia (ALL) is known to vary by geographic location and ethnic origin. This study aimed to determine the frequency of hypodiploidy, ETV6-RUNX1, BCR-ABL1, and MLL rearrangement within New Zealand's pediatric ALL population and to assess whether the frequency of these ALL prognostic markers varies according to ethnicity.
The New Zealand Children's Cancer Registry provided information for all registered pediatric ALL patients that were diagnosed between 2000 and 2009, with medical records available for 246 patients. Each patient's medical record was reviewed to determine the frequency of hypodiploidy, ETV6-RUNX1, BCR-ABL1, MLL rearrangement, and cell lineage. Chi-square tests for independence were undertaken to compare the frequencies of cytogenetic abnormalities according to prioritized ethnicity.
The frequency of cytogenetic ALL abnormalities in the New Zealand pediatric population were consistent with international reference values. A low frequency of ETV6-RUNX1 was evident for Maori pediatric ALL patients (5.4%, P = 0.018), when compared to Pacific peoples (21.1%) and non-Maori/non-Pacific peoples (27.4%). This has not impacted on outcome, however, with equivalent 5-year overall survival being observed in Maori (89.4%) compared to Pacific peoples (92.0%) and non-Maori/non-Pacific peoples (90.2%).
A lower frequency of the favorable prognostic marker ETV6-RUNX1 was observed in Maori pediatric ALL patients. This did not translate into poorer survival. Future research into biological and nonbiological prognostic factors in this patient population may assist in explaining this finding.
已知小儿急性淋巴细胞白血病(ALL)中常见细胞遗传学异常的频率因地理位置和种族起源而异。本研究旨在确定新西兰小儿ALL人群中低二倍体、ETV6-RUNX1、BCR-ABL1和MLL重排的频率,并评估这些ALL预后标志物的频率是否因种族而异。
新西兰儿童癌症登记处提供了2000年至2009年间所有登记的小儿ALL患者的信息,其中246例患者有病历可供查阅。查阅每位患者的病历以确定低二倍体、ETV6-RUNX1、BCR-ABL1、MLL重排的频率以及细胞系。进行卡方独立性检验以比较按优先种族划分的细胞遗传学异常频率。
新西兰小儿人群中细胞遗传学ALL异常的频率与国际参考值一致。与太平洋岛民(21.1%)和非毛利/非太平洋岛民(27.4%)相比,毛利小儿ALL患者中ETV6-RUNX1的频率较低(5.4%,P = 0.018)。然而,这并未影响预后,毛利人(89.4%)、太平洋岛民(92.0%)和非毛利/非太平洋岛民(90.2%)的5年总生存率相当。
在毛利小儿ALL患者中观察到有利预后标志物ETV6-RUNX1的频率较低。但这并未导致生存率降低。对该患者群体的生物学和非生物学预后因素进行进一步研究可能有助于解释这一发现。